Pathways Connecting Late-Life Depression and Dementia DOI Creative Commons
Christoph Linnemann, Undine E. Lang

Frontiers in Pharmacology, Год журнала: 2020, Номер 11

Опубликована: Март 13, 2020

REVIEW article Front. Pharmacol., 13 March 2020Sec. Neuropharmacology Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.00279

Язык: Английский

Role of tau protein in Alzheimer's disease: The prime pathological player DOI
Shibi Muralidar, Senthil Visaga Ambi, Saravanan Sekaran

и другие.

International Journal of Biological Macromolecules, Год журнала: 2020, Номер 163, С. 1599 - 1617

Опубликована: Авг. 9, 2020

Язык: Английский

Процитировано

184

APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease DOI Creative Commons
Zonghua Li, Francis Shue, Na Zhao

и другие.

Molecular Neurodegeneration, Год журнала: 2020, Номер 15(1)

Опубликована: Ноя. 4, 2020

Abstract Investigations of apolipoprotein E ( APOE ) gene, the major genetic risk modifier for Alzheimer’s disease (AD), have yielded significant insights into pathogenic mechanism. Among three common coding variants, APOE*ε4 increases, whereas APOE*ε2 decreases late-onset AD compared with APOE*ε3 . Despite increased understanding detrimental effect , it remains unclear how confers protection against AD. Accumulating evidence suggests that protects through both amyloid-β (Aβ)-dependent and independent mechanisms. In addition, has been identified as a longevity suggesting systemic on aging process. However, is not entirely benign; carriers exhibit certain cerebrovascular diseases neurological disorders. Here, we review from human animal studies demonstrating protective propose working model depicting potential underlying Finally, discuss therapeutic strategies designed to leverage APOE2 treat

Язык: Английский

Процитировано

184

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease DOI
Konstantinos Avgerinos, Luigi Ferrucci, Dimitrios Kapogiannis

и другие.

Ageing Research Reviews, Год журнала: 2021, Номер 68, С. 101339 - 101339

Опубликована: Апрель 5, 2021

Язык: Английский

Процитировано

177

Prevention of dementia in an ageing world: Evidence and biological rationale DOI Creative Commons
Giulia Grande, Chengxuan Qiu, Laura Fratiglioni

и другие.

Ageing Research Reviews, Год журнала: 2020, Номер 64, С. 101045 - 101045

Опубликована: Март 19, 2020

As the population ages, number of people with dementia is expected to increase in coming decades, consequences at societal and individual levels. In this narrative review, we provide a summary scientific evidence concerning prevention, focus on following three strategies: 1) Targeting body protect brain, including prevention treatment cardiovascular morbidity; 2) Compensatory interventions counteract brain ageing, education life-long engagement cognitively socially stimulating activities; 3) Lifespan health promotion, such as physically active lifestyle, smoking cessation, healthy balanced diet. Next, consider biological mechanisms by which these strategies may act taking into account main pathways implicated development progression dementia: neurodegeneration, resilience, vascular damage, neuroinflammation, oxidative stress. Based current evidence, line declining trends incidence high-income countries, conclude that timely multidomain preventive actions are promising reduce epidemic worldwide. There still considerable gap between epidemiological its underlying mechanisms. Filling will be crucial move forward

Язык: Английский

Процитировано

176

Pathways Connecting Late-Life Depression and Dementia DOI Creative Commons
Christoph Linnemann, Undine E. Lang

Frontiers in Pharmacology, Год журнала: 2020, Номер 11

Опубликована: Март 13, 2020

REVIEW article Front. Pharmacol., 13 March 2020Sec. Neuropharmacology Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.00279

Язык: Английский

Процитировано

169